International Assets Investment Management LLC Has $21.35 Million Stock Holdings in Moderna, Inc. (NASDAQ:MRNA)

International Assets Investment Management LLC boosted its holdings in shares of Moderna, Inc. (NASDAQ:MRNA - Free Report) by 10,687.1% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 319,514 shares of the company's stock after purchasing an additional 316,552 shares during the period. International Assets Investment Management LLC owned approximately 0.08% of Moderna worth $21,353,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also added to or reduced their stakes in MRNA. Vontobel Holding Ltd. raised its holdings in shares of Moderna by 148.2% during the third quarter. Vontobel Holding Ltd. now owns 116,088 shares of the company's stock valued at $7,758,000 after acquiring an additional 69,313 shares during the period. Profund Advisors LLC raised its holdings in shares of Moderna by 20.9% during the second quarter. Profund Advisors LLC now owns 56,218 shares of the company's stock valued at $6,676,000 after acquiring an additional 9,719 shares during the period. Tobam raised its holdings in shares of Moderna by 121.6% during the third quarter. Tobam now owns 27,794 shares of the company's stock valued at $1,857,000 after acquiring an additional 15,249 shares during the period. Swedbank AB raised its holdings in shares of Moderna by 149.6% during the third quarter. Swedbank AB now owns 85,099 shares of the company's stock valued at $5,687,000 after acquiring an additional 51,000 shares during the period. Finally, Marshall Wace LLP raised its holdings in shares of Moderna by 295.5% during the second quarter. Marshall Wace LLP now owns 35,200 shares of the company's stock valued at $4,180,000 after acquiring an additional 26,300 shares during the period. 75.33% of the stock is owned by institutional investors and hedge funds.

Moderna Stock Performance

Shares of NASDAQ MRNA traded down $0.50 during trading hours on Wednesday, hitting $54.72. 4,275,632 shares of the stock were exchanged, compared to its average volume of 4,345,481. The company has a debt-to-equity ratio of 0.05, a current ratio of 4.09 and a quick ratio of 3.92. The company's 50 day moving average is $66.34 and its 200 day moving average is $102.02. The firm has a market capitalization of $20.97 billion, a P/E ratio of -3.52 and a beta of 1.66. Moderna, Inc. has a one year low of $52.26 and a one year high of $170.47.

Moderna (NASDAQ:MRNA - Get Free Report) last posted its quarterly earnings data on Thursday, August 1st. The company reported ($3.33) earnings per share (EPS) for the quarter, topping the consensus estimate of ($3.47) by $0.14. The business had revenue of $241.00 million during the quarter, compared to the consensus estimate of $128.41 million. Moderna had a negative net margin of 116.18% and a negative return on equity of 21.35%. Moderna's quarterly revenue was down 29.9% compared to the same quarter last year. During the same period in the prior year, the firm earned ($3.62) EPS. On average, research analysts expect that Moderna, Inc. will post -9.88 EPS for the current year.

Insider Buying and Selling

In other Moderna news, CFO James M. Mock sold 1,321 shares of the stock in a transaction on Wednesday, August 28th. The shares were sold at an average price of $79.39, for a total value of $104,874.19. Following the completion of the sale, the chief financial officer now directly owns 8,600 shares of the company's stock, valued at $682,754. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other Moderna news, CFO James M. Mock sold 1,321 shares of the stock in a transaction on Wednesday, August 28th. The shares were sold at an average price of $79.39, for a total value of $104,874.19. Following the completion of the sale, the chief financial officer now directly owns 8,600 shares of the company's stock, valued at $682,754. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO James M. Mock sold 715 shares of the stock in a transaction on Monday, October 7th. The shares were sold at an average price of $60.12, for a total transaction of $42,985.80. Following the completion of the sale, the chief financial officer now directly owns 9,505 shares of the company's stock, valued at approximately $571,440.60. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 3,184 shares of company stock valued at $238,531. Company insiders own 15.70% of the company's stock.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on the stock. JPMorgan Chase & Co. lowered shares of Moderna from a "neutral" rating to an "underweight" rating and cut their price target for the company from $88.00 to $70.00 in a report on Friday, September 13th. Barclays dropped their price objective on shares of Moderna from $155.00 to $125.00 and set an "overweight" rating on the stock in a research note on Monday, September 16th. Royal Bank of Canada reiterated a "sector perform" rating and issued a $75.00 price objective on shares of Moderna in a research note on Thursday, September 19th. UBS Group dropped their price objective on shares of Moderna from $140.00 to $108.00 and set a "buy" rating on the stock in a research note on Thursday, October 24th. Finally, Hsbc Global Res upgraded shares of Moderna from a "moderate sell" rating to a "hold" rating in a research note on Wednesday, August 28th. Two analysts have rated the stock with a sell rating, fourteen have given a hold rating and four have issued a buy rating to the company's stock. Based on data from MarketBeat.com, Moderna presently has an average rating of "Hold" and an average price target of $94.65.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.